Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRIS
Introduction Intracranial atherosclerotic disease (ICAD) is one of the most prevalent causes of stroke across the world, with a high morbidity and mortality rate. Endovascular treatment (ET) has gained prominence but remains a challenge with unfavorable results. Recent literature has demonstrated th...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Stroke: Vascular and Interventional Neurology |
| Online Access: | https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.009 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387488025509888 |
|---|---|
| author | Saisree Farhan Ravi S Syed Khalid Inamullah Khan Wondwossen G Tekle Omar Tanweer Jan‐Karl Burkhardt Pascal M Jabbour Stavropoula Tjoumakaris Nabeel A Herial Adnan H Siddiqui Ramesh Grandhi Adnan I Qureshi Ameer E Hassan |
| author_facet | Saisree Farhan Ravi S Syed Khalid Inamullah Khan Wondwossen G Tekle Omar Tanweer Jan‐Karl Burkhardt Pascal M Jabbour Stavropoula Tjoumakaris Nabeel A Herial Adnan H Siddiqui Ramesh Grandhi Adnan I Qureshi Ameer E Hassan |
| author_sort | Saisree |
| collection | DOAJ |
| description | Introduction Intracranial atherosclerotic disease (ICAD) is one of the most prevalent causes of stroke across the world, with a high morbidity and mortality rate. Endovascular treatment (ET) has gained prominence but remains a challenge with unfavorable results. Recent literature has demonstrated that the Resolute Onyx Zotarolimus‐Eluting stent (RO‐ZES) is a technically safe option with low complication rates. Preliminary data has also reported the 30‐day outcomes associated with intracranial stent placement for ICAD with RO‐ZES compared to results from the Stenting Versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Here, we aim to compare outcomes at 1 year with the SAMMPRIS trial to further evaluate the efficacy and outcomes of RO‐ZES in a multicenter study with long‐term follow up extending beyond 30 days. Methods Prospectively maintained databases across 7 stroke centers were reviewed to identify adult patients undergoing RO‐ZES placement for treatment of ICAD between January 2019 to May 2023. The primary endpoint was composite of 1‐year stroke, ICH, and/or death. This data was propensity score matched using age, sex, hypertension, diabetes mellitus, smoking status, and impacted vessel for comparison between RO‐ZES and the SAMMPRIS percutaneous angioplasty and stenting groups (S‐PTAS). Results A total of 104 patients met the inclusion criteria for analysis (mean age 62.6, 31.7% female). Impacted vessels included basilar artery (6.7%), internal carotid artery (26.9%), middle cerebral artery (29.8%), posterior cerebral artery (1.0%), and vertebral artery (35.6%). Propensity score match analysis of the 104 patients with S‐PTAS demonstrated 1‐year stroke, ICH, and/or death rate of 11.5% in the RO‐ZES group and 35.6% in the S‐PTAS group (OR 4.17, 95% CI 2.06‐8.96, p=0.001). Conclusion The RO‐ZES system provides a not only safe and effective alternative to other traditional stents, but also demonstrates strong potential to reduce long‐term complications at 1 year compared with the S‐PTAS group. Further prospective multicenter studies are needed to corroborate the findings and compare RO‐ZES directly with other stents. |
| format | Article |
| id | doaj-art-759d09ba4ffc4e558994bf46e056f0ea |
| institution | Kabale University |
| issn | 2694-5746 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stroke: Vascular and Interventional Neurology |
| spelling | doaj-art-759d09ba4ffc4e558994bf46e056f0ea2025-08-20T03:53:47ZengWileyStroke: Vascular and Interventional Neurology2694-57462023-11-013S210.1161/SVIN.03.suppl_2.009Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRISSaisree0Farhan1Ravi S2Syed Khalid3Inamullah Khan4Wondwossen G Tekle5Omar Tanweer6Jan‐Karl Burkhardt7Pascal M Jabbour8Stavropoula Tjoumakaris9Nabeel A Herial10Adnan H Siddiqui11Ramesh Grandhi12Adnan I Qureshi13Ameer E Hassan14Department of Neurology Houston Methodist Hospital Houston Texas United StatesUniversity of Missouri Columbia Missouri USADepartment of Neurosurgery University of Missouri Columbia Missouri USADepartment of Neurosurgery University of Illinois ‐ Chicago United StatesDepartment of Neurosurgery University of Missouri Columbia Missouri USADepartment of Neurology Valley Baptist‐University of Texas Rio Grande Valley Harlingen Texas United StatesDepartment of Neurosurgery Baylor College of Medicine Houston Texas United StatesDepartment of Neurosurgery Hospital of the University of Pennsylvania Penn Medicine Philadelphia Pennsylvania USADepartment of Neurosurgery Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Neurosurgery Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Neurosurgery Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Neurosurgery University of Buffalo Buffalo New York USADepartment of Neurosurgery University of Utah Salt Lake City Utah USAZeenat Qureshi Stroke Institute and Department of Neurology University of Missouri Columbia Missouri USADepartment of Neurology Valley Baptist‐University of Texas Rio Grande Valley Harlingen Texas United StatesIntroduction Intracranial atherosclerotic disease (ICAD) is one of the most prevalent causes of stroke across the world, with a high morbidity and mortality rate. Endovascular treatment (ET) has gained prominence but remains a challenge with unfavorable results. Recent literature has demonstrated that the Resolute Onyx Zotarolimus‐Eluting stent (RO‐ZES) is a technically safe option with low complication rates. Preliminary data has also reported the 30‐day outcomes associated with intracranial stent placement for ICAD with RO‐ZES compared to results from the Stenting Versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Here, we aim to compare outcomes at 1 year with the SAMMPRIS trial to further evaluate the efficacy and outcomes of RO‐ZES in a multicenter study with long‐term follow up extending beyond 30 days. Methods Prospectively maintained databases across 7 stroke centers were reviewed to identify adult patients undergoing RO‐ZES placement for treatment of ICAD between January 2019 to May 2023. The primary endpoint was composite of 1‐year stroke, ICH, and/or death. This data was propensity score matched using age, sex, hypertension, diabetes mellitus, smoking status, and impacted vessel for comparison between RO‐ZES and the SAMMPRIS percutaneous angioplasty and stenting groups (S‐PTAS). Results A total of 104 patients met the inclusion criteria for analysis (mean age 62.6, 31.7% female). Impacted vessels included basilar artery (6.7%), internal carotid artery (26.9%), middle cerebral artery (29.8%), posterior cerebral artery (1.0%), and vertebral artery (35.6%). Propensity score match analysis of the 104 patients with S‐PTAS demonstrated 1‐year stroke, ICH, and/or death rate of 11.5% in the RO‐ZES group and 35.6% in the S‐PTAS group (OR 4.17, 95% CI 2.06‐8.96, p=0.001). Conclusion The RO‐ZES system provides a not only safe and effective alternative to other traditional stents, but also demonstrates strong potential to reduce long‐term complications at 1 year compared with the S‐PTAS group. Further prospective multicenter studies are needed to corroborate the findings and compare RO‐ZES directly with other stents.https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.009 |
| spellingShingle | Saisree Farhan Ravi S Syed Khalid Inamullah Khan Wondwossen G Tekle Omar Tanweer Jan‐Karl Burkhardt Pascal M Jabbour Stavropoula Tjoumakaris Nabeel A Herial Adnan H Siddiqui Ramesh Grandhi Adnan I Qureshi Ameer E Hassan Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRIS Stroke: Vascular and Interventional Neurology |
| title | Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRIS |
| title_full | Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRIS |
| title_fullStr | Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRIS |
| title_full_unstemmed | Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRIS |
| title_short | Abstract 009: 1‐Year Outcomes of Resolute Onyx Zotarolimus‐Eluting Stent for Intracranial Atherosclerotic Disease: Multicenter Comparison with SAMMPRIS |
| title_sort | abstract 009 1 year outcomes of resolute onyx zotarolimus eluting stent for intracranial atherosclerotic disease multicenter comparison with sammpris |
| url | https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.009 |
| work_keys_str_mv | AT saisree abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT farhan abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT ravis abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT syedkhalid abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT inamullahkhan abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT wondwossengtekle abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT omartanweer abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT jankarlburkhardt abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT pascalmjabbour abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT stavropoulatjoumakaris abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT nabeelaherial abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT adnanhsiddiqui abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT rameshgrandhi abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT adnaniqureshi abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris AT ameerehassan abstract0091yearoutcomesofresoluteonyxzotarolimuselutingstentforintracranialatheroscleroticdiseasemulticentercomparisonwithsammpris |